AptarGroup : J.P. Morgan Healthcare Conference - January 16, 2025

Published: 2025-01-16 11:24:04 ET ATR

Stephan Tanda

President & CEO

Vanessa Kanu

Chief Financial Officer

Gael Touya

President, Aptar Pharma

43rd Annual J.P. Morgan

Healthcare Conference

January 16, 2025

1

Aptar is a Global Leader in Drug and Consumer Product Dosing, Dispensing and Protection Technologies

2023 % of Total Reported Sales

We combine product design, engineering and science to

Home Care

3%

Personal

Care

16%

Beverage

Food

4%

Proprietary Drug

10%

Delivery Devices3

31%

Closures

20%

$3.5B2 Pharma 44%

Beauty

36%

Injectables

8%

65%

Pharma % of Total FY 2023

Adj EBITDA1

23%

Beauty % of

Total FY 2023

Adj EBITDA1

13%

create core differentiating technologies.

Proprietary drug delivery systems provide a competitive edge, driven by a strong innovation pipeline and over 7,000 active and pending patents in our portfolio.

Each segment has attractive growth potential. Consistently recognized as a sustainability leader.

Robust balance sheet providing ample opportunity to deploy firepower - 1-3x leverage corridor long-term target.

Over the last five years, we have returned about $780M to shareholders through dividends and share repurchases.

Beauty

Active Material

23%

Science Solutions

5%

Closures % of Total FY 2023

Adj EBITDA1

1: Adjusted EBITDA - See Appendix for definition.

2: 2023 Annual Revenue.3

3: Proprietary Drug Delivery Devices includes Prescription, Consumer Healthcare and Digital health Markets.

Global Presence and Customer Base

9 Mos. 2024 Net Sales by Ship To Destination

EMEA

50%

North

Asia

11%

America

31%

Latin America

8%

Over 13,000 dedicated employees in 20 countries

Significant history and global presence enables us to build solid and lasting credibility with regional and global powerhouse customers

Data presented on this slide as of first 9 mos. 2024.

4

Technology, Innovation and Sustainability Leader

Technology and

Trusted Partner with

Sustainability is a

Deep End-User and

Growth Driver and

Innovation Leader

Regulatory Expertise

Competitive Advantage

1: APF FuturityTM compared to conventional APF solution. Based on a simplified LCA of Raw Materials only, using avoided burden

5

approach. Calculated with Aptar Eco-design tool, developed in collaboration with Sphera. No third-party review has been performed.

Technologies and Industrial Capabilities Deployed Across End Markets

Technology Platforms & Industrial Capabilities

Pharma

Beauty

Personal Care Home Care

Beverage

Food

Dispensing Fine Mist Pumps

In Place

Dispensing Closures

Developing

Dispensing Lotion Pumps

Proprietary

Active Materials

Technology

Elastomeric Components

Platforms1

Airless Systems

Aerosol Valves & Bag-On-Valves

Services

Digital + Connected Devices

Precision Injection Molding

Industrial

High Speed Assembly, AI QC2

Capabilities

Metal Stamping & Anodizing

Decoration

Sustainable Solutions

1:

Only Technology Platforms that achieved more than $100M in sales in 2022.

6

2:

Artificial Intelligence assisted Quality Control.

Aptar's Value

Creation

Framework

Active in Growing End Markets, with a Leading Position in

01 Key Categories

02 Technology, Innovation & Sustainability Leader

• Know-how and regulatory expertise

03 Continued Portfolio Evolution Through Balanced Capital Allocation & Strategic M&A

04 Focused on Cost Management & Operational Leverage

05 Strong Balance Sheet that Provides Optionality

7

Intentional Capital Allocation

2019 - 9 Mos. 2024

Repurchases - $0.3B

Dividends - $0.6B

10%

20%

53%

17%

CapEx - $1.6B

Acquisitions - $0.5B

• Pharma ~52%

• Pharma ~55%

We remain focused on selective and disciplined capital allocation

8

Long-Term Targets

Aptar

Long-Term Targets

Long-Term Targets

set in 2021

set in 2023

Core Sales Growth

4-7%

4-7%

Adjusted EBITDA / Sales%

20-22%

21-23%

ROIC1

10-13%

11-13%

Dividend Payout Ratio

30-40%

30-40%

Leverage Corridor

1-3X

1-3X

Aptar Pharma

Core Sales Growth

6-10%

7-11%

Adjusted EBITDA / Sales%

32-36%

32-36%

Aptar Beauty

Core Sales Growth

3-6%

3-6%

Adjusted EBITDA / Sales%

15-17%

15-17%

Aptar Closures2

Core Sales Growth

n/a

4-7%

Adjusted EBITDA / Sales%

n/a

16-18%

1: Excluding M&A transactions less than one year old.

2. Targets for Food and Beverage Segment were Core Sales: 6-10% and EBITDA margin 18-20%.9 For all non-GAAP measures on this page, relevant definitions can be found in the Appendix.

Consistent Track Record of Returning Capital to Shareholders

$120 $110 $100 $90 $80 $70 $60 $50 $40 $30 $20 $10 $0

31st Consecutive Year Increasing

Annual Dividend Paid

'94 '95 '96 '97 '98 '99 '00 '01 '02 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13 '14 '15 '16 '17 '18 '19 '20 '21 '22 '23 '24

Shareholder returns are an important part of our capital allocation strategy, historically dividend target payout ratios of 30-40% of Adjusted EPS

10

Disclaimer

AptarGroup Inc. published this content on January 16, 2025, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on January 16, 2025 at 16:23:06.374.